Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy
At ASH 2024, Professor Paolo Ghia discusses the BRUIN CLL-321 phase 3 trial, which demonstrates the efficacy of pirtobrutinib, a non-covalent BTK inhibitor, in patients with relapsed/refractory CLL who previously received covalent BTK inhibitors. The study shows prolonged progression-free survival and manageable side effects and is the first study to address this patient population in a relapsed/refractory setting.
